
    
      The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone
      (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time
      (IELT) male patients with primary premature ejaculation.
    
  